Yeh, I think the only credit I can gave to BSR is the bargain opportunity that's created. When this stock is back at $6 again, we might all be looking back and saying thanks to him.
I really wish similar short attack occur to NVDA, LGND, COST, and alike :)
The "Honig Syndrome" might turn out to be profitable distraction. Even though this stock will ultimately be driven by the success (of lack) of Niagen/pTeroPure, etc.
On Q2, an EPS of $0.02 should be thought of as extraordinary. The operating leverage is just beginning to show its existence. Growing revenue should be falling to bottom line rapidly, as Niagen scales up in the next 12-18 months. We should be adapting our views as we go along.
Market Data 
Markets 
AI
